Number of days with data, mean values, standard deviation (SD), median, max–maximum recorded value, interquartile range (IQR = Q3-Q1, Q1 – 25^th percentile, Q3 – 75^th percentile).

<p>Edmonton, Canada, 1992–2002.</p

ORs and 95% CIs for ED visits for substance use disorders for an IQR change in the levels of the named pollutant.

<p>The ORs are reported for same day (0) as well as lags 1–7 days. Left-hand panel—whole period: January—December, right-hand panel—cold period: October–March. Horizontal error bars represent the 95% CIs; where the CI would not fit on the figure an arrowhead is used to denote that it continues. Black dots represent ORs, grey squares represent weights.</p

ORs and 95% CIs for ED visits for substance use disorders for one IQR value for nitrogen dioxide (NO₂) lagged by 2 days.

<p>ORs are reported for 67 age groups. Upper panel—whole period (January–December), lower panel—cold period (October–March).</p

The correlation between air pollution levels for three monitoring stations (E–east, N–northwest, C–central).

<p>Edmonton, Canada, 1992–2002.</p

The estimated correlations calculated pairwise.

<p>Upper triangle represents the coefficients for all data; lower triangle for cold period data. Edmonton, Canada, 1992–2002.</p

Number of days with data (NW–left-hand part in warm season, NC–right-hand part in cold season), mean values, standard deviation (SD), median, Max–maximum recorded value.

<p>Edmonton, Canada, 1992–2002.</p

ORs and 95% CIs for ED visits for substance use disorders along IQR values for carbon monoxide.

<p>The ORs are reported for same day (0) as well as lags 1–7 days. Left-hand panel—whole period: January—December, right-hand panel—cold period: October–March. Colored areas represent the 95% CIs.</p

Plasma levels of bigET-1, ET-1, ET-2 and ET-3 peptides in animals treated with AEOL.

<p>Mean ± SE, n = 6 animals per group. <b>A.</b> BigET-1: NS. <b>B.</b> ET-1: Two-way ANOVA. TIME main effect, p = 0.042. Holm-Sidak: <b>a</b>, 2 h vs 24 h, p < 0.05. AEOL main effect, p = 0.001. Holm-Sidak: <b>b</b>, 0, 2 vs 5 mg/kg, p < 0.001. <b>C.</b> ET-2: NS. <b>D.</b> ET-3: Two-way ANOVA. AEOL main effect, p = 0.014. Holm-Sidak: <b>c</b>, 2 vs 5 mg/kg, p = 0.004.</p

Plasma levels of isoprostane and 3-nitrotyrosine in animals treated with AEOL.

<p>Mean ± SE, n = 6 animals per group. <b>A</b>. Plasma isoprostane: Two-way ANOVA. AEOL main effect, p = 0.036. Holm-Sidak: <b>a</b>, 0 vs 2 mg/kg, p = 0.011. <b>B</b>. Plasma 3-nitrotyrosine: Two-way ANOVA. AEOL main effect, p = 0.003. Holm-Sidak: <b>b</b>, 0 vs 5 mg/kg, p < 0.001, and 2 vs 5 mg/kg, p < 0.040.</p

Lung and heart eNOS and iNOS mRNA.

<p>Mean ± SE, n = 6 animals per group. <b>A.</b> Lung eNOS: NS. <b>B.</b> Heart eNOS: NS. <b>C.</b> Lung iNOS: Two-way ANOVA. TIME x AEOL interaction, p < 0.001. Holm-Sidak: <b>a</b>, AEOL within 2 h: 0, 2 vs 5mg/kg, p < 0.001. <b>b</b>, AEOL within 24 h: 0 vs 5 mg/kg, p = 0.047. <b>D.</b> Heart iNOS: NS.</p